T1	PROC 46 74	Estudio de Extensión abierto
T2	PROC 80 100	evaluar la seguridad
#1	AnnotatorNotes T2	C1705187; Safety Study; Research Activity
T3	PROC 137 165	Estudio de extensión abierto
T4	PROC 545 548	OLE
#2	AnnotatorNotes T4	C1709323; Open Label Study; Research Activity (?)
T5	PROC 231 265	evaluar la seguridad y la eficacia
#3	AnnotatorNotes T5	C0511730; Identify product efficacy and safety issues; Health Care Activity
T6	DISO 311 354	hipercolesterolemia familiar heterocigótica
#4	AnnotatorNotes T6	C0342882; Familial hypercholesterolemia - heterozygous; Disease or Syndrome
T7	DISO 592 595	HFH
#5	AnnotatorNotes T7	C0342882; Familial hypercholesterolemia - heterozygous; Disease or Syndrome
T8	DISO 378 406	Hipercolesterolemia Familiar
#6	AnnotatorNotes T8	C0020445; Hypercholesterolemia, Familial; Disease or Syndrome
T9	DISO 433 476	Hipercolesterolemia Heterocigótica Familiar
#7	AnnotatorNotes T9	C0342882; Familial hypercholesterolemia - heterozygous; Disease or Syndrome
T10	PROC 577 588	diagnóstico
#8	AnnotatorNotes T10	C0011900; Diagnosis; Diagnostic Procedure
T11	PROC 803 812	protocolo
#9	AnnotatorNotes T11	C0008971; Clinical Protocols; Therapeutic or Preventive Procedure
T12	PROC 895 906	tratamiento
#10	AnnotatorNotes T12	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T13	DISO 931 953	Acontecimiento adverso
#11	AnnotatorNotes T13	C0877248; Adverse event; Pathologic Function
T14	CHEM 104 114	Alirocumab
#12	AnnotatorNotes T14	C3491162; alirocumab; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T15	CHEM 283 293	alirocumab
#13	AnnotatorNotes T15	C3491162; alirocumab; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T16	Date 13 17	2013
T17	Date 266 279	a largo plazo
T18	LIVB 297 306	pacientes
#14	AnnotatorNotes T18	C0030705; Patients; Patient or Disabled Group
T21	LIVB 507 516	pacientes
#15	AnnotatorNotes T21	C0030705; Patients; Patient or Disabled Group
T22	LIVB 565 572	mujeres
#16	AnnotatorNotes T22	C0043210; Woman; Population Group
T23	LIVB 857 869	investigador
#17	AnnotatorNotes T23	C0035173; Research Personnel; Professional or Occupational Group
T24	LIVB 921 929	paciente
#18	AnnotatorNotes T24	C0030705; Patients; Patient or Disabled Group
T20	LIVB 555 562	varones
#19	AnnotatorNotes T20	C0025266; Male population group; Population Group
T19	Observation 876 906	incumplimiento del tratamiento
#20	AnnotatorNotes T19	C0184543; Noncompliance with therapeutic regimen; Finding
R1	Overlap Arg1:T5 Arg2:T17	
R2	Experiences Arg1:T18 Arg2:T15	
R3	Experiences Arg1:T18 Arg2:T6	
R4	Experiences Arg1:T20 Arg2:T7	
R5	Experiences Arg1:T22 Arg2:T7	
R6	Experiences Arg1:T21 Arg2:T7	
T25	CONC 616 625	inclusión
#21	AnnotatorNotes T25	C1512693; Inclusion; Qualitative Concept
R7	Overlap Arg1:T7 Arg2:T25	
T26	Observation 661 682;694 702	completado uno de los estudios
#22	AnnotatorNotes T26	C2732579; Completion of clinical trial; Finding
R9	Overlap Arg1:T19 Arg2:T12	
R11	Experiences Arg1:T24 Arg2:T12	
T27	Observation 969 1002	suspensión definitiva del estudio
R12	Causes Arg1:T13 Arg2:T27	
#23	AnnotatorNotes T3	C1709323; Open Label Study; Research Activity (?)
#24	AnnotatorNotes T1	C1709323; Open Label Study; Research Activity (?)
#25	AnnotatorNotes T17	C0443252; Long-term; Temporal Concept
A1	Experiencer T18 Patient
A2	Experiencer T21 Patient
A3	Experiencer T20 Patient
A4	Experiencer T22 Patient
A5	Experiencer T23 Other
A6	Experiencer T24 Patient
